 The FLAME Study is a 16-week, open randomized comparative effectiveness trial evaluating genomic predictors and biomarkers of response and adverse events to treatment with lamotrigine n200 and fluoxetine n200 for bipolar I, II and bipolar schizoaffective depressed adults 18-65. Participants will be recruited over a 5-year period. 